Adakveo (Crizanlizumab) stock recall following end of UK marketing authorisation
On January 10th 2024, the Crizanlizumab licence was revoked by the Medicines and Healthcare products Regulatory Agency (MHRA). This meant that the NHS would have to end using it as a treatment for sickle cell disorder. Since that day, no new patients have been able to start on Crizanlizumab for the first time.
People who were already using Crizianlizumab before that decision are still able to continue using the treatment. However stocks of Crizanlizumab in pharmacies are being recalled from 21st February 2024. After this date Crizanlizumab will no longer be available to patients.
It is important that patients using Crizanlizumab speak to their consultant haematologist to discuss alternative treatments if they have not already done so.